Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors

Steven W. Pipe, MD, Michael Recht, MD PhD, Michael U. Callaghan, MD, Robert F. Sidonio, Jr., MDMSc, Jerry Grandoni, PhD, Veronique Duretz, Daniel Bonzo, PhD, Jean Luc Plantier, PhD, Sean Evans, PhD RPh, Ian S Mitchell, PhD, Cedric Hermans, MDMRCP,PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136430

Published: 2020

Journal Articles

Reverting Rivaroxaban Effect By Activated Factor X: Assessment Using Thrombin Generation Assay

Dominique Grenier, Meyer Michel Samama, Professor, Sami Chtourou, Ph. D., Jean-Luc Plantier, PhD

Blood (2014) 124 (21): 2868.

https://doi.org/10.1182/blood.V124.21.2868.2868

Published: 2014

Journal Articles

Evaluation of the Antithrombin Potential in a Thrombin Generation Assay Performed at the Surface of Endothelial Cells

Béatrice Catieau, Sami Chtourou, Ph. D., Jean-Luc Plantier, PhD

Blood (2014) 124 (21): 4168.

https://doi.org/10.1182/blood.V124.21.4168.4168

Published: 2014

Journal Articles

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

Nathalie Enjolras, PhD, Yesim Dargaud, MD, PhD, Jean-Luc Plantier, PhD, Heli Simpson, Florine Guillaume, Claude Negrier, MD

Blood (2009) 114 (22): 4202.

https://doi.org/10.1182/blood.V114.22.4202.4202

Published: 2009

Journal Articles

Substitution of Four Residues Revealed by High-Throughput Screening of Human Factor VIII A2 Domain Generated a Recombinant Molecule That Escapes to Anti-Factor VIII Antibodies

Jean-Luc Plantier, Didier Saboulard, Marc Delcourt, Nathalie Enjolras, Claude Negrier, MD

Blood (2008) 112 (11): 3067.

https://doi.org/10.1182/blood.V112.11.3067.3067

Published: 2008

Journal Articles

Generation of Factor VIII Molecules Partially Resistant to Activated Protein C.

Veronique Rolli, Ph D, Nathalie Enjolras, PhD, Cecile Ducasse, Marie-Helene Rodriguez, PhD, Thomas Weimer, PhD, Hans-Peter Hauser, PhD, Claude Negrier, MD, PhD, Jean-Luc Plantier, Ph D

Blood (2004) 104 (11): 1729.

https://doi.org/10.1182/blood.V104.11.1729.1729

Published: 2004

NARROW

In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors

Reverting Rivaroxaban Effect By Activated Factor X: Assessment Using Thrombin Generation Assay

Evaluation of the Antithrombin Potential in a Thrombin Generation Assay Performed at the Surface of Endothelial Cells

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

Substitution of Four Residues Revealed by High-Throughput Screening of Human Factor VIII A2 Domain Generated a Recombinant Molecule That Escapes to Anti-Factor VIII Antibodies

Generation of Factor VIII Molecules Partially Resistant to Activated Protein C.

Email alerts

ASH Publications

American Society of Hematology

In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors

Reverting Rivaroxaban Effect By Activated Factor X: Assessment Using Thrombin Generation Assay

Evaluation of the Antithrombin Potential in a Thrombin Generation Assay Performed at the Surface of Endothelial Cells

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

Substitution of Four Residues Revealed by High-Throughput Screening of Human Factor VIII A2 Domain Generated a Recombinant Molecule That Escapes to Anti-Factor VIII Antibodies

Generation of Factor VIII Molecules Partially Resistant to Activated Protein C.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only